The American Academy of Dermatology’s Annual Meeting in San Diego provided an opportunity for researchers to share their latest findings. Below is a summary of some of the data presented at the meeting:
TARGET-DERM AA Poster Outlines Unmet Need, Disease Burden of AA Patients
New patient-reported outcomes data presented in a poster at AAD 2024 confirms the high unmet need and significant disease burden that patients with moderate to severe alopecia areata experience.
“What’s important about our data presented at AAD and TARGET-DERM AA is that we are gaining insights on the impact of the disease. There are meaningful ways that this data can help inform improved assessment and treatment by healthcare professionals, ultimately changing the trajectory of disease progression and quality of life for patients,” said Michael W. Fried, MD, FAASLD, co-founder and chief medical officer, Target RWE.
10xBio Abstract Shows Promising Results for Novel Injectable for Submental Body Contouring
A late-breaking research abstract by 10xBio shows initial clinical trial results from a randomized, double-blind, placebo-controlled study of 10XB101, a novel injectable drug for submental body contouring.
“The results of this study clearly demonstrated far superior efficacy and tolerability for 10XB101 than the currently marketed body contouring drug, deoxycholate, which I have more than 10 years of experience with,” said Mitchel P. Goldman, MD, a dermatologic surgeon and medical director of Cosmetic Laser Dermatology. “In addition, its attributes hold promise for potential expansion to other body contouring applications, such as treatment of the abdomen and flanks.”
Pelage Pharmaceuticals’ Late-Breaking Data on Novel Small Molecule for Hair Growth
Pelage Pharmaceuticals presented Phase 1 clinical data on PP405, a novel small molecule therapy that reactivates dormant hair follicle stem cells to trigger hair growth.
“This therapy represents an exciting new option for not only treating but reversing hair loss. We look forward to advancing PP405 to Phase 2 clinical studies this year,” said Daniel Gil, PhD, CEO of Pelage Pharmaceuticals.
Ascletis Pharma Inc. Poster Shows Phase II Results of a Fatty Acid Synthase Inhibitor for Acne
Ascletis Pharma presented a poster that showed final results from its Phase II study of the first fatty acid synthase inhibitor to treat acne vulgaris.
“The FASN inhibitor ASC40 is a first-in-class drug candidate with novel mechanism, demonstrating significant efficacy and good safety in the Phase II clinical trial. Currently, the enrollment of Phase III clinical trial of ASC40 for acne is accelerating. We expect to bring more benefits for acne patients in the future,” said Jinzi J. Wu, PhD, founder, chairman and CEO of Ascletis.
Eli Lilly and Company’s Data on First-of-its-Kind Lebrikizumab Study
Eli Lilly and Company presented Phase 3 data from a study of lebrikizumab, specifically designed for people with skin of color and moderate-to-severe atopic dermatitis.
“Lebrikizumab is the first investigative treatment for atopic dermatitis to disclose robust efficacy data specifically for people with skin of color, who may experience barriers to treatment or inequitable care,” said Mark Genovese, MD, senior vice president of Immunology Development at Lilly.
Amgen’s Late-Breaking Phase 3 Results from Study of Oral Otezla in Children with Psoriasis
Amgen presented 52-week results from the Phase 3 SPROUT study of Otezla (apremilast) in children and teens 6 to 17 years old with moderate to severe plaque psoriasis.
“For the first time, we have a full year of data on a potential oral treatment for children and adolescents with moderate to severe plaque psoriasis, who currently lack any approved oral treatment options,” said Loretta Fiorillo, MD, FRCPC, clinical professor of pediatrics, University of Alberta. “At 52 weeks, more than half of patients achieved clear or almost clear skin. Otezla showed increased efficacy beyond that seen at the week 16 primary endpoint, with a durable maintenance of response – an important finding for families living with this chronic inflammatory disease.”
UCB’s Late-Breaking Four-Year Efficacy and Safety of Plaque Psoriasis Therapy
UCB announces results of a four-year look into the efficacy and safety of BIMZELX (bimekizumab-bkzx) for adults with moderate-to-severe plaque psoriasis.
“Analysis shows that through four years of bimekizumab treatment, over six out of ten patients achieved and maintained complete skin clearance, a clinically meaningful endpoint and outcome for patients. These long-term data will be highly welcomed by the dermatology community since they provide important considerations for clinical practice,” said Bruce Strober, MD, PhD, clinical professor of dermatology at Yale University, and Central Connecticut Dermatology.
Johnson & Johnson’s Data on Oral Peptide to Block IL-23 Receptor
Johnson & Johnson presented data evaluating JNJ-2113, an investigational targeted oral peptide designed to block the IL-23 receptor in people with moderate-to-severe plaque psoriasis.
“Data from the FRONTIER 2 study showed that the skin clearance as seen by PASI 75 and higher-bar PASI 90 and 100 responses at 16 weeks was maintained at 52 weeks with no new safety signals across all JNJ-2113 treatment groups,” said Laura Ferris, MD, PhD, professor of dermatology, University of Pittsburgh. “These findings suggest the potential for JNJ-2113 to continue delivering clinically meaningful results, and addresses the high unmet need for a novel, durable, and convenient oral therapeutic option for people living with moderate-to-severe plaque psoriasis.”
Burt’s Bees’ Posters on Benefits of Nature-Based Products
Burt’s Bees presented three posters on the benefits of nature-based products in improving skin barrier function and hydration, and supporting the skin microbiome in people with atopic dermatitis and rosacea.
Stanley Levy, MD, a board-certified dermatologist in Chapel Hill, N.C., and study consultant, said, “This research demonstrates that a topical nature-based gel cream containing inulin, an effective prebiotic, can assist in supporting a balanced microbiome in patients with mild to moderate acne and replenish moisture content without provoking breakouts.”
